Grand Pharmaceutical Group Limited (HKG:0512)

Market Cap	17.26B -41.4%
Revenue (ttm)	12.48B +5.9%
Net Income	1.11B -47.3%
EPS	0.32 -47.3%
Shares Out	3.50B
PE Ratio	15.56
Forward PE	9.67
Dividend	0.17 (3.43%)
Ex-Dividend Date	Jun 12, 2026

Volume	4,010,000
Open	4.850
Previous Close	4.850
Day's Range	4.835 - 4.955
52-Week Range	4.530 - 8.970
Beta	0.67
Analysts	Strong Buy
Price Target	9.53 (+93.31%)
Earnings Date	Aug 26, 2026

About HKG:0512

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additive...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 12,326
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0512

Financial Performance

In 2025, HKG:0512's revenue was 12.28 billion, an increase of 5.48% compared to the previous year's 11.64 billion. Earnings were 1.24 billion, a decrease of -49.73%.

Analyst Summary

According to 4 analysts, the average rating for 0512 stock is "Strong Buy." The 12-month stock price target is $9.53, which is an increase of 93.31% from the latest price.

Price Target

$9.53

(93.31% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error